A significant reduction of EphA7 expression in human colorectal cancers was shown using semiquantitative reverse transcription-polymerase chain reaction analysis in 59 colorectal cancer tissues, compared to corresponding normal mucosas (P ¼ 0.008), and five colon cancer cell lines. To investigate the mechanism of EphA7 downregulation in colorectal cancer, we examined the methylation status of the 5 0 CpG island around the translation start site in five colon cancer cell lines using restriction enzymes, methylation-specific PCR, and bisulfite sequencing and found evidence of aberrant methylation. The expression of EphA7 in colon cancer cell lines was restored after treatment with 5-aza-2 0 -deoxycytidine. Analysis of methylation status in totally 75 tumors compared to clinicopathological parameters revealed that hypermethylation of colorectal cancers was more frequent in male than in female (P ¼ 0.0078), and in moderately differentiated than in well-differentiated adenocarcinomas (P ¼ 0.0361). There was a tendency that hypermethylation in rectal cancers was more frequent than in colon cancers (P ¼ 0.0816). Hypermethylation was also observed in colorectal adenomas. This is the first report describing the downregulation of an Eph family gene in a solid tumor via aberrant 5 0 CpG island methylation. It provides the evidence that EphA7 gene is involved in human colorectal carcinogenesis.
Introduction
The Eph family, named for its expression in an erythropoietin-producing human hepatocellular carcinoma cell line (Hirai et al., 1987) , is the largest subfamily of tyrosine kinase receptors and includes at least 14 distinct receptors and eight distinct ligands. Eph receptors have been divided into two groups based on the nature of their corresponding ligands and their sequence homology: EphA and EphB receptors (Eph Nomenclature Committee, 1997) . The ligands for the Eph receptors are the ephrins: the ephrinA subclass is linked to the membrane through a GPI linkage, while the ephrinB subclass is a transmembrane protein.
Ephrins and Ephs are essential for embryonic development (Chin-Sang et al., 1999 , 2002 Frisen et al., 1999) and for the differentiation of the nervous and vascular systems (Friedman and O'Leary, 1996; Adams, 2002) . They also play a role in angiogenesis (Favre et al., 2003; Sullivan and Bicknell, 2003) . In recent years, some of the Eph genes have been found to be overexpressed in human tumors, including neuroblastoma (Tang et al., 1999) , lung carcinoma (Tang et al., 1999) , gastric cancer (Kiyokawa et al., 1994; Kataoka et al., 2002) , esophageal cancer (Miyazaki et al., 2003) , breast cancer (Wu et al., 2004) , and colorectal cancer (Stephenson et al., 2001; Liu et al., 2002 Liu et al., , 2004 Kataoka et al., 2004) . Among the Eph family genes, relatively less attention has been directed toward EphA7 in human tumors, and the potential role of EphA7 in human oncology has not been addressed. Recently, we noticed a loss of expression of EphA7 during an investigation on alterations in the expression of Eph family genes in human digestive cancers (Kataoka et al., 2002 (Kataoka et al., , 2004 . EphA7, previously known as Mdk1, Hek11, Ehk-3, Ebk, and Cek11, was originally isolated from adult mouse brain (Ciossek et al., 1995; Valenzuela et al., 1995) . EphA7 has the same major structural features as the other members of the Eph family, including a cysteine-rich region and tandem fibronectin type-III domains in its extracellular portion. In mice, EphA7 is expressed not only in its conventional full-length version, containing the intracellular tyrosine kinase domain but also in a truncated form that lacks this domain (Ciossek et al., 1995; Valenzuela et al., 1995) . So far, the possible role of EphA7 in human colorectal cancer has not been investigated, although the overexpression of EphB4, EphA2, and Ephrin B2 has been documented in human colorectal cancer. In this study, we used semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) to conduct an EphA7 expression analysis in human colorectal cancer tissues.
Since we found that the expression of EphA7 was significantly downregulated in 29 out of 59 (49%, tumor: normal mucosa ratio o0.5) colorectal cancer tissues, compared to normal mucosa samples, we further analysed the possible mechanism of the downregulation of EphA7 in human colorectal cancer. In the present report, we describe the methylation of 5 0 CpG islands in the region around the EphA7 translation start site in colorectal cell lines and in a considerable portion of primary colorectal cancers, and its clinicopathological significance in totally 75 cases of colorectal cancers.
Results

Loss of EphA7 expression in primary colorectal cancers and colon cancer cell lines
Using semiquantitative RT-PCR, we examined the expression of EphA7 in 59 primary colorectal cancer cases, five colon cancer cell lines, and some other cancer cell lines. EphA7 was significantly downregulated in 29 out of 59 (49%, tumor: normal mucosa ratio o0.5) of the colorectal cancer tissues, compared to expression level in paired normal mucosa samples (Figure 1) . A statistical analysis (SPSS Japan Inc., Tokyo, Japan) revealed that EphA7 was significantly downregulated in colorectal cancers, compared to corresponding normal tissues (P ¼ 0.008). The expression of EphA7 was detected by RT-PCR in the colon cancer cell line SW480, while the loss of EphA7 expression was observed in the DLD1, HT29, HCT116, and SW620 cell lines (Figure 2 ). The expression of EphA7 in several other cancer cell lines of different tissue origins varied (data not shown). Quantitative real time RT-PCR was also carried out in 12 of these 59 cases. The protocol was the same as that we previously reported (Tao et al., 2004) . We got the consistent results to semiquantitative RT-PCR using isotope (data not shown).
We analysed various clinicopathological parameters of the cases in relation to the downregulated status of EphA7. Since some methylations are believed to relate Figure 1 EphA7 mRNA expression in primary colorectal cancer tissues (normal mucosas and tumor samples). Semiquantitative RT-PCR using 32 P-labeled dCTP was carried out to determine the expression of EphA7 mRNA. The mRNA of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also detected as a control for the integrity of the RNA samples as well as an internal control. The gel was dried and subjected to autoradiography and image analysis. The expression level (radiation dose unit PSL) was measured using a Fujix BAS1000 (MacBAS; Fuji Film, Tokyo, Japan). All RI (radio-isotope) count values, including those for GAPDH, were transformed using a logarithm. The relative expression of EphA7 in the paired tumor and normal mucosa samples from 59 colorectal cancer patients were then studied 0   DLD1  HCT116  HT29  SW480  SW620  293T  NCI-H1299  1N  1T  2N  2T  3N There are genetic and epigenetic reasons for the loss of expression of certain genes. We screened the colon cancer cell lines and other cell lines for EphA7 genomic mutations using a single-strand conformation polymorphism (SSCP) analysis. No mutations were found in any of the colon cancer cell lines that lacked EphA7 expression. We therefore assumed that the downregulation of EphA7 in colorectal cancer was due to an epigenetic alteration. First of all, to determine whether methylation was responsible for the loss of EphA7 in colorectal cancer, we treated three colon cancer cell lines (DLD1, HCT116, and SW620) that lacked EphA7 expression with the demethylation reagent 5-aza-2 0 -deoxycytidine for 2 or 5 days. EphA7 mRNA expression was detected by RT-PCR in all three cell lines after the treatment. The restored expression level varied in the different cell lines and was time-dependent ( Figure 3) . Next, we postulated that 5 0 CpG islands in the area from À605 to 515 bp (from translation start site) (Figure 6a ) may be hypermethylated; this area is close to the basic promoter of EphA3, another member of the EphA gene family, which has been previously characterized (Dottori et al., 1999) . EphA7 showed a 56.1% mRNA homology to EphA3. We next used three methods to detect the methylation status of the 5 0 CpG islands in this area.
The methylation status of the 5 0 CpG islands was first determined by digestion with the methylation-sensitive and nonsensitive restriction enzymes HpaII and MspI, respectively, followed by PCR in five colon cancer cell lines (DLD1, HCT116, HT29, SW480, and SW620). No PCR bands were detected in all five colorectal cancer cell lines after MspI digestion, while PCR bands were seen in DLD1, HCT116, HT29, and SW620 after HpaII digestion. However, a PCR band was not observed in SW480 after HpaII digestion. These data indicate that the 5 0 CG at the enzyme-recognized sites (5 0 CCGG) are methylated in DLD1, HCT116, HT29, and SW620, but not in SW480 (Figure 4a ). The methylation status of 30 CpGs from À578 to À158 bp (from translation start site) was analysed in five colon cancer cell lines by cloning the PCR products to pGEM-T Easy vector (Promega). The hypermethylation of 5 0 CpG island was confirmed in these five colon cancer cell lines ( Figure 5 , Supplementary Figure 1 ). The methylation status of these 30 CpGs was also analysed in a normal musosa from colorectal patient in which the EphA7 expression was downregulated (ratio of expression EphA7 in tumor to normal was 0.043). The results showed that all 30 CpG sites were unmethylated in normal mucosa (Supplementary Figure 2) Next, we determined the methylation status in the region from À605 to 515, The expression of EphA7 gene was restored in the DLD1, HCT116 and SW620 colon cancer cell lines after treatment with the methylation inhibitor 5-aza-2 0 -deoxycytidine. The cell lines were treated with 5-aza-2 0 -deoxycytidine for 2 or 5 days. Total RNA was harvested before (0 days) and after treatment (2 and 5 days). Semiquantitative RT-PCR was carried out to evaluate the expression of EphA7 mRNA. EphA7 expression was recovered in all three tested colon cancer cell lines by treatment with 5-aza-2 0 -deoxycytidine
The methylation status of the 5 0 CpG islands upstream of the translation start site in the DLD1, HCT116, HT29, SW480, and SW620 colon cancer cell lines was determined by digestion with methylation-sensitive restriction enzymes, followed by PCR. In total, 1 mg of DNA from the colon cancer cell lines was digested with either MspI (M) or HpaII (H), followed by PCR amplification. (b) MSP analysis of the colon cancer cell lines (DLD1, HCT116, HT29, SW480, SW620), four examples of primary colorectal cancers, one lymphoma cell line (BALL-1), one lung cancer cell line (NCI-H1299) and one human embryonic kidney cell line (293T). PCR was carried out to detect methylated (ME) and unmethylated DNA (UN) using primer sets designed for methylated and unmethylated DNA, respectively (Figure 6c ), the CpG methylation status of the upstream group was found to strongly relate to the expression of EphA7 (Figure 6 ). Finally, the genomic DNAs of five colon cancer cell lines (DLD1, HCT116, HT29, SW480, and SW620) were subjected to bisulfite modification, followed by methylation-specific PCR (MSP) (Figure 4b ). Methylated DNA was detected in all of the above five colon cancer cell lines. Unmethylated DNA was strongly detected in SW480 and very weakly detected in HT29.
Hypermethylation of 5 0 CpG island in tumors related to sex, pathological classification, and location of tumors
In 13 primary colorectal cancers that EphA7 expression was downregulated, methylated DNA was detected in 12 tumors and weekly detected in four normal mucosas. In four cases that EphA7 was not downregulated, methylated DNA was weakly detected in one case of both tumor and normal mucosa (Table 2) . Then MSP was used for further extensive study. In order to analyse the clinicopathological significance of hypermethylation of 5 0 CpG island in EphA7, we carried out MSP to 75 primary colorectal cancers. In the 75 primary colorectal cancers, (A) there were 37 cases that methylated DNAs only detected in tumors, not detected in matched normal mucosas; (B) 32 cases that methylated DNAs were not detected both in tumors and matched normal mucosas; (C) methylated DNAs were detected both in tumors and matched normal mucosas in six cases. Unmethylated DNAs were detected in all normal mucosas, and most of tumors. We analysed the relation between clinicopathological parameters and MSP results using SAS 9.1 soft (Table 3) . In this analysis, the significant difference was shown between male and female (P ¼ 0.0078). The hypermethylation of EphA7 more frequently occurred in male colorectal cancer patients than in female A: methylated DNA detected only in tumor, not in normal mucosa; B: methylated DNA not detected in both tumor and normal mucosa; C: methylated DNA detected in both tumor and normal mucosa; Fisher's exact test was performed; SAS 9.1 was used EphA7 in human colorectal cancer J Wang et al patients. That hypermethylation of 5 0 CpG island in EphA7 gene is not caused by aging was confirmed by MSP (P ¼ 0.8067). When analysis of relation between pathological classification and MSP, the P-volume was 0.0867 if including all three types of pathological classification (well differentiated, moderately differentiated, and mucinous adenocarcinoma). Considering that mucinous type is a rare type (only two in 75 cases of colorectal cancers), we analysed the relation between MSP and pathological classification that only including well-differentiated and moderately differentiated adenocarcinomas, and detected the significant difference (P ¼ 0.0361). Hypermethylation of EphA7 was more frequently detected in rectal tumors than in colon cancers (P ¼ 0.0816). We also analysed other clinicopathological parameters including lymphatic metastases, depth of parietal invasion, macroscopic type (Bormann classification), presence of lymph (ly) and blood vessel invasions (v), according to the general rules for clinical and pathological studies on caner of the colon, rectum, and anus (Japanese society for caner of the colon and rectum, 1998), and Dukes classification, but no correlation was detected.
Immunohistochemical characterization and EphA7 level in tumors
A tissue microarray consisting of paired tumor and normal mucosa specimens from all 59 cases was made, and several immunohistological characterizations were performed (Table 4 ). EphA7 expression was significant different between chromogranin A positive and negative tumors (P ¼ 0.003).
Discussion
Documentation on the expression of EPH family receptor tyrosine kinases and ephrin ligands in various physiological and pathological settings is accumulating. These reports indicate that Eph receptors and their ligands may be associated with various characteristics of human tumors. The upregulation of the expression of several members of the Eph family of receptor tyrosine kinases has been reported (Easty et al., 1999; Liu et al., 2002; Miyazaki et al., 2003; Fox and Kandpal, 2004) . We previously reported that EPHB2 is overexpressed in gastric cancer (Kiyokawa et al., 1994; Kataoka et al., 2002) and that EphA2 is overexpressed in colorectal cancer (Kataoka et al., 2004) .
In the present study, we found that EphA7 was downregulated in colorectal cancers. This is the first study to report the downregulation of an Eph family gene in colorectal cancer. In the development of colorectal cancer, a series of tumor suppressor genes are inactivated by mutations, methylation, and chromosomal deletions. Velculescu and co-workers published the results of their kinome projects, which included the kinase domains in Eph, and reported that 5% of all colon cancer cell lines have a mutation in their EphA3 kinase domain (Bardelli et al., 2003) . We screened all the exons of EphA7 in the colon cancer cell lines used in this study but found only a passenger mutation (data not shown) at a very low frequency. The hypermethylation of 5 0 CpG islands has been shown to inactivate a number of cancer-associated genes, such as hMLH1 (Cunningham et al., 1998), PTEN (Goel et al., 2004) , p14 (Shen et al., 2003) , and p16INK4a (Hsieh et al., 1998; Wiencke et al., 1999) , in colorectal cancers. Since we observed a specific downregulation in the colorectal cancers, we ascribed an epigenetic origin to the cancerous changes in the colonic mucosas. Hypermethylation of the 5 0 CpG islands in EphA7 in five colon cancer cell lines was detected using metylation-sensitive restriction enzymes, MSP, and bisulfite sequencing. In the area of the EphA7 genomic sequence from À605 to 515 from translation start site, 80 CG sites were identified and were divided into an upstream group and a downstream group. Our results clearly showed that the methylation of the upstream CpG islands was strongly correlated with the expression of EphA7. In the DLD1, HCT116, HT29, and SW620 colon cancer cell lines, in which EphA7 expression was absent, most of the upstream CpG sites were methylated. While in 293T, which highly expressed EphA7, most of the upstream CpG sites were unmethylated; in SW480 and NCI-H1299 in which EphA7 modestly expressed, some of the upstream CpG sites were unmethylated. Based on this methylation profile, we believe that the methylation of 5 0 CG islands before the translation start site is responsible for EphA7 downregulation. This correlation was also confirmed by the methylation profiles in other cell lines of different tissue origins (data not shown here). Next, three colon cancer cell lines that lose their expression of EphA7 mRNA were treated with the methyltransferase inhibitor 5-aza-2 0 -deoxycytidine. The EphA7 expression was The tumor was considered positive when the number of stained cell was higher than 10% in the section. SAS Release 9.1 was used EphA7 in human colorectal cancer J Wang et al restored in all of these cell lines after treatment. These data indicate that aberrant methylation of the 5 0 CpG islands may be one mechanism that leads to the downregulation of EphA7 in colorectal cancer.
Importantly, this phenomenon occurs in vivo. We checked the methylation status in 75 primary colorectal cancers and paired normal mucosas to determine whether methylation occurs in vivo using MSP. Methylated DNA was detected in 37(49%) primary colorectal cancer samples and not detected in matched nontumor mocosas (bisulfite sequencing results also confirmed that 30 upstream CpG sites in one of these normal mucosas were unmethylated) (Supplementary Figure 2) . Methylated DNA was not detected both in tumors and matched mucosas of 32 cases (43%). Of six cases (8%), methylated DNA was detected in both of tumors and matched mucosas. Unmethylated DNA bands were detected in all normal mucosa and weakly detected in most of the primary tumors. The presence of unmethylated DNA in the primary cancers can be explained by the fact that the tumor tissue may have contained some normal epithelial cells. The faint detection of methylated DNA in normal mucosa can be explained by either tumor cell infiltration, a tumor predisposing event in the colorectal mucosa near the tumor, or some other inflammatory or reparative situation in the mucosa. The results of MSP in primary colorectal cancers and bisulfite sequencing of normal colon musosas showed that hypermethylation of EphA7 is not a colonic specific event. The hypermethylation of CpG islands is one of the most common epigenetic alterations in human cancers. Recently, researchers have begun to address the clinical significance of hypermethylation. Brock et al. (2003) reported that the methylation of multiple genes in esophageal adenocarcinoma was an independent and strong predictor for disease-specific recurrence and patient survival. First, we did not find any obvious strong relationship between the downregulation of EphA7 and particular clinicopathological parameters in the colorectal cancers that were examined for expressions. This finding may be due to the small number of cases (29 cases) in which EphA7 downregulated. Alternately it was because of contamination of blood cells and endothelial cells in the cancer specimens. Then we expanded colorectal cancers cases to 75 for MSP and found intriguing correlation between methylation of 5 0 CpG island and some of the clinicopathological parameters such as histological grade of differentiation. Eph gene family is essential for embryonic development and for differentiation of the nervous and vascular systems (Friedman and O'Leary, 1996; Adams, 2002; Aoki et al., 2004) . Our results showed that EphA7 may play a role in the differentiation of colorectal caner. Hypermethylation of 5 0 CpG island in tumor was more frequently occurred in moderately differentiated than in well-differentiated tumors (P ¼ 0.0361). This may imply that EphA7 protein may take part in the regulation of cell differentiation in colorectal cancer. Furthermore, hypermethylation of EphA7 gene in tumors was significantly different between in male and female (P ¼ 0.0078). From these data, we postulated that hypermethylaton of EphA7 gene may be correlated to some environmental factors such as diet, tobacco smoking, and alcohol drinking. Although the difference is not statistically significant, our MSP data showed that hypermethylation of EphA7 is more prevalent in rectum than in colon (P ¼ 0.0816).
Interestingly, the colon cancer cell lines SW480 and SW620 had different EphA7 expression profiles and different CpG methylation profiles, in spite of having originated from the same cancer patient. SW480 was established from a primary adenocarcinoma of the colon (according to ATCC cell line data), and SW620 was initiated by Leibovitz et al. from a lymph node obtained from the same patient 1 year later, when a recurrence of the malignancy appeared. In our data, EphA7 expression was detected in SW480 and was lost in SW620. SW480 and SW620 also had different CpG methylation status in their upstream regions according to the results of bisulfite sequencing. Methylated DNA was detected in SW620, but only partially detected in SW480, and unmethylated DNA was only detected in SW480, and not in SW620 using the MSP method. This would indicate that the methylation of CpG islands in EphA7 may occur during the progression of colorectal cancer, as in this patient. The potential application of the methylation of CpG islands in the EphA7 gene as a molecular marker for predicting the occurrence and recurrence of colorectal cancer must be profoundly studied in the next round of experiments. We have already detected hypermethylation in three out of five colon adenomas (data not shown). This suggests that the downregulation of EphA7 is an early event during the initiation of colorectal carcinogenesis.
Furthermore, as shown in Figure 1 , a certain subset of colon cancers exhibits EphA7 overexpression. We examined the immunohistopathological features of these cases (Table 4) . Using tissue microarray containing 59 cancer tissues, which we examined EphA7 RNA expression, we immunostained p53, b-catenin, E-cadherin, chromogranin A and CD34. The prevalence of the positive of these markers was 44, 64, 6.7, 20 , and 62%, respectively. Interestingly, EphA7 expression was significant greater in chromogranin A positive tumor than in the negative ones (P ¼ 0.003), suggesting EphA7 expression may be paralleled to neuroendocrine cell differentiation. In vitro characterization of EphA7 overexpressing tumor cells is undergoing.
In conclusion, downregulation of EphA7 due to methylation in human colorectal cancer confers certain biological and histopathological tint to its carcinogenesis and differentiation.
Materials and methods
Specimens and cell lines
All human colorectal carcinoma specimens and corresponding normal tissues were obtained from surgical resections performed at Hamamatsu University School of Medicine in Japan between 1999 and 2004; the study protocol has been approved by the Institutional Review Board of Hamamatsu Univertsity Five colon cancer cell lines (DLD1, HCT116, HT29, SW480, and SW620) were used in the study. The cells were routinely maintained in Dulbecco's modified Eagle's medium (NISSUI Pharmaceutical Co., Tokyo, Japan) supplemented with 1 mM L-glutamine, 10% FBS (Life Technologies, Inc.), 100 U/ml of penicillin G and 100 mg/ml of streptomycin. Cells were incubated at 371C in a humidified atmosphere of 95% air and 5% CO 2 .
Semi-quantitative RT-PCR
The exponential phase of the PCR amplification of EphA7 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for the quantitative analysis. PCR amplification was performed in a DNA thermal cycler (PC-700; ASTEC, Fukuoka, Japan). In total, 30 cycles of amplification for the GAPDH internal control and 35 cycles for EphA7 were performed as follows: denaturation at 941C for 1 min followed by primer annealing at 581C for 1 min and extension at 721C for 1 min, with a final extension at 721C for 10 min. The RT-PCR primer sets for EphA7 were designed between two exons (exons 3 and 4) to avoid genomic DNA contamination. Several other sets of primers covering all the exons of EphA7 were also tested to monitor the efficiency of amplification. The nucleotide sequences were obtained from GenBank (Accession Number: XM_004485). The sense primer was 5 0 -TCTTTA GTCGAGGTTCGAGG-3 0 and the antisense primer was 5 0 -TGTGCATGCAACGTATGGTG-3 0 . The PCR products were 312 bp long. The sense primer for GAPDH (GenBank Accession Number: BT007877) was 5 0 -GAAGGTGAAGG TCGGAGTCA-3 0 . The antisense primer for GAPDH was 5 0 -TTGAGGTCAATGAAGGGGTC-3 0 . The PCR products were 108 bp long. The PCR products were separated by electrophoresis on 8% polyacrylamide gels at room temperature under a voltage of 150 for 1 h. The gel was then dried and subjected to autoradiography and image analysis. The expression level (radiation dose unit PSL) was measured using a Fuji BAS1000 (MacBAS; Fuji Film, Tokyo Japan). All radioisotope (RI) count values, including those for GAPDH, were transformed using a logarithm for further statistical analysis. The count of each RNA message proportional to that of GAPDH was then determined.
Quantitative Real time RT-PCR was carried out using QuantiTect SYBR Green PCR kit (QIAGEN) and Roche Molecular Biochemicals LightCycler. The transcript of housekeeping gene porphobilinogen deaminase (PBGD) was used as an internal control. PBGD-pGEM-T Easy vector and EphA7-pcDNA3.1( þ ) plasmid DNA were diluted to make the standard curve. The primer sets and reaction conditions for amplifying PBGD and EphA7 are available when requiring. cDNAs from 12 cases of colorectal cancers that semiquantitative RT-PCR carried out were subjected to quantitative real time RT-PCR. The volume of tumor/normal mucosa of EphA7/PBGD was compared with that of EphA7/GAPDH using isotope.
Statistical analysis
The ratio of EphA7 expression in the tumor to that in normal tissue in each case was transformed using a common logarithm. For statistical comparisons of these log-transformed data among two or more groups, an ANOVA was used. When comparing two groups, a t-test was used. All statistical analyses were performed using SPSS software, version 11.5 (SPSS Japan Inc., Tokyo, Japan). For all of the statistical tests, a two-sided P-value of less than 0.05 was considered statistically significant. The SAS 9.1 software was used when analysis of correlation between EphA7 expression, MSP results, immunohistochemical staining results, and clinicopathological parameters.
Methylation-sensitive restriction enzyme and PCR
The methylation status of the 5 0 CpG island upstream of translation start site was determined by digestion with methylation-sensitive restriction enzymes followed by PCR. In total, 1 mg of genomic DNA was digested using MspI and HpaII (TOYOBO, Japan) restriction enzymes. The digested DNAs were precipitated with ethanol and dissolved in 30 ml of dH 2 O. Then, 1 ml aliquots were analysed by PCR in 30 ml reactions, followed by a 1.5% agarose gel check. The primer sequences for the methylation sensitive-restriction PCR were 5 0 -GCTATAGAAAAGAGTGTAAG-3 0 (forward) and 5 0 -CTCCACACTCCAATAATATC-3 0 (reverse). The PCR products were 378 bp long and included three enzyme restriction sites (5 0 CCGG). The basic principle of this method was described by Endo et al. (1995) .
Methylation-specific PCR (MSP)
Genomic DNA was modified by sodium bisulfite, as described by Clark et al. (1994) and Herman et al. (1996) . Primers were designed to discriminate between methylated and unmethylated alleles following bisulfite treatment. Primer sequences were chosen for the regions containing frequent CpG and CpG pairs near the 3 0 end of the primers to provide maximal discrimination between methylated and unmethylated DNA. In total, 2 ml aliquots were amplified in a 20 ml reaction mixture consisting of 1 Â buffer (10 mM Tris-HCl, 2.0 mM MgCl 2 , 50 mM KCl, pH 8.3), 0.5 U HotStarTaq (Qiagen), 260 mM dNTPs, and 0.3 mM of the primer sets. The PCR conditions were as follows: 951C for 15 min, then 35 cycles of 941C for 30 s, 581C (for detection of methylated DNA) or 531C (for detection of unmethylated DNA) for 30 s, 721C for 1 min and finally 10 min at 721C. The methylation specific primer set was 5 0 -ATTTGATTTCGTTCGGTATC-3 0 (forward) and 5 0 -CTC CGACTACAAACCGACCG-3 0 (reverse). The unmethylation specific primer set was 5 0 -ATTTGATTTTGTTTGGTATT-3 0 (forward) and 5 0 -CTCCAACTACAAACCAACCA-3 0 (reverse). Primer sets for detection of methylated and unmethylated DNA were located at the same sites of genomic sequence (forward primer was located at À432 to À413 from translation start site; reverse primer was located at À223 to À204) (Figure 6a ). The PCR products were 229 bp long. The PCR EphA7 in human colorectal cancer J Wang et al products were run on an 8% nondenaturing polyacrylamide gel, followed by ethidium bromide staining.
Bisulfite genomic sequencing
In total, 2 ml of bisulfite-treated genomic DNA was PCR amplified by three primer sets in a 30 ml reaction mixture consisting of 1 Â buffer (10 mM Tris-HCl, 1.5 mM MgCl 2 , 50 mM KCl, pH 8.3), 260 mM of each dNTP, 400 mM of primer, and 1.2 U of Taq polymerase. The PCR conditions were as follows: 951C for 3 min, then 35 cycles of 941C for 45 s, 501C or 581C or 601C for 1 min, 721C for 1 min and finally 10 min at 721C. The three primer sets used for bisulfite sequencing were 5 0 -TATAGAAAAGAGTGTAAGTTG-3 0 (forward) and 5 0 -CTCCACACTCCAATAATATC-3 0 (reverse), PCR product ¼ 375 bp; 5 0 -GATATTATTGGAGTGTGGAG-3 0 (forward) and 5 0 -CCATCACCTTACCTTCCTTC-3 0 (reverse), PCR products ¼ 356 bp; and 5 0 -AAGGAAGGTAAGGTGATGGG-3 0 (forward) and 5 0 -CCAGTCTCCAACCCAACTCT-3 0 (reverse), PCR product ¼ 424 bp. We could not find the ideal primer sequence without C for reverse primer flank to downstream CpG island, then designed this primer according to the protocol available from http://www.mdanderson.org/ leukemia/methylation/bpcr.html. The PCR products were purified using a QIAquick PCR purification kit (QIAGEN). The PCR products were subjected to direct sequencing or cloned into pGEM-T Easy vector (Promega); 12 colonies of each sample were picked up and subjected to PCR using primer set of T7 and SP6, and sequenced using the Big Dye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Japan) on a 3100 Genetic Analyser (Applied Biosystems, HITACHI Japan), according to the manufacturer's protocol.
5-aza-2
0 -deoxycytidine treatment of colon cancer cell lines
Cells were plated at a density of 3 Â 10 5 cells/100 mm on day 0 and treated with freshly prepared 5-aza-2 0 -deoxycytidine (Sigma) after 24 h. In total, 10 ml of 2 mM 5-aza-2 0 -deoxycytidine were added to a total medium volume of 10 ml (final concentration, 2 mM). The medium was changed 24 h after treatment. RNA was obtained at 2 and 5 days after the start of treatment. Total RNA was extracted, and reverse transcription was performed. The expression of EphA7 mRNA in colon cancer cell lines was detected by semiquantitative RT-PCR.
Genomic mutation screening in cell lines by SSCP
Five colon cancer cell lines (DLD1, HT29, HCT116, SW480, and SW620), six gastric cancer cell lines (TMK1, MKN1, MKN28, MKN74, KATOIII, and AGS), and three lung cancer cell lines (NCI-H460, NCI-H1299, and A549) were screened for genomic mutations in EphA7 using SSCP in all 17 exons. SSCP was performed under three conditions: at room temperature with or without 5% glycerol and at 41C without glycerol. The sequences of the primer sets are available on request.
Abbreviations GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MSP, methylation specific PCR; PCR, polymerase chain reaction.
